Shares of Moderna (MRNA) climbed over 12% in early trading as retail investors on Reddit amplified momentum, despite ongoing scrutiny of the company’s cash burn rate. Market watchers remain divided between speculative optimism and caution over financial sustainability.
- Moderna (MRNA) rose over 12% on increased retail investor activity
- Cash burn reached $1.8 billion over 12 months as of Dec. 31, 2025
- Cash and equivalents totaled $2.1 billion, potentially sustainable for ~18 months
- Revenue from COVID-19 vaccines now accounts for <30% of total revenue
- Net short position on MRNA increased to 6.8% of float
- Price-to-sales ratio of 1.9x exceeds biotech sector median of 1.2x
Moderna (MRNA) surged more than 12% in pre-market trading following renewed retail investor interest on social platforms. The rally was fueled by a wave of speculative posts on Reddit, where users highlighted the potential for mRNA-based therapies beyond COVID-19, particularly in cancer and universal influenza vaccines. The stock closed the previous session at $102.87, with volume exceeding 25 million shares—well above its 30-day average of 14.2 million. Despite the rally, institutional investors and analysts remain cautious. Moderna reported a trailing twelve-month cash burn of $1.8 billion, with $2.1 billion in cash and equivalents as of December 31, 2025. This implies the company may exhaust its current liquidity in approximately 18 months if R&D and operational costs remain unchanged. The cash burn is exacerbated by a 20% decline in revenue from its core COVID-19 vaccine line, which now represents less than 30% of total revenue versus 75% in 2022. The broader market reacted with muted volatility. The VIX index (^VIX) rose 2.1% to 18.7, reflecting slight risk-off sentiment, while crude oil futures (CL=F) dipped 0.6% to $78.30 per barrel amid mixed macroeconomic indicators. The divergence highlights how retail-driven momentum in individual stocks can occur independently of macroeconomic trends. The rally has attracted attention from short-sellers, who now hold a net short position of 6.8% of float, up from 4.2% at the start of the year. Analysts caution that without a clear path to profitability from its pipeline—particularly in oncology—Moderna’s valuation remains vulnerable to sentiment shifts. The stock’s price-to-sales ratio stands at 1.9x, significantly above the biotech sector median of 1.2x.